A Modular Phase I/IIa, Multi-centre, Dose Escalation, and Expansion Study of AZD3470, a MTA Cooperative PRMT5 Inhibitor, as Monotherapy and in Combination with Anti cancer Agents in Patients with Advanced/Metastatic Solid Tumours That are MTAP Deficient.
Principal Investigator
Dr. F. Opdam
Drugs
AZD3470, a MTA Cooperative PRMT5 Inhibitor.
This is a first time in human (FTiH) Phase I/IIa, open-label, multi-centre study of AZD3470 in participants with advanced or metastatic solid tumors with MTAP deficiency. The study consists of several study modules, evaluating the safety, tolerability, pharmacokinetic (PK), pharmacodynamics, and preliminary efficacy of AZD3470 as monotherapy or in combination with other anti-cancer agents.
Read more on clinicaltrials.gov.